BACKGROUND: To detect attention deficit hyperactivity disorder (ADHD) in treatment seeking substance use disorders (SUD) patients, a valid screening instrument is needed. OBJECTIVES: To test the performance of the Adult ADHD Self-Report Scale V 1.1(ASRS) for adult ADHD in an international sample of treatment seeking SUD patients for DSM-IV-TR; for the proposed DSM-5 criteria; in different subpopulations, at intake and 1-2 weeks after intake; using different scoring algorithms; and different externalizing disorders as external criterion (including adult ADHD, bipolar disorder, antisocial and borderline personality disorder). METHODS: In 1138 treatment seeking SUD subjects, ASRS performance was determined using diagnoses based on Conner's Adult ADHD Diagnostic Interview for DSM-IV (CAADID) as gold standard. RESULTS: The prevalence of adult ADHD was 13.0% (95% CI: 11.0-15.0%). The overall positive predictive value (PPV) of the ASRS was 0.26 (95% CI: 0.22-0.30), the negative predictive value (NPV) was 0.97 (95% CI: 0.96-0.98). The sensitivity (0.84, 95% CI: 0.76-0.88) and specificity (0.66, 95% CI: 0.63-0.69) measured at admission were similar to the sensitivity (0.88, 95% CI: 0.83-0.93) and specificity (0.67, 95% CI: 0.64-0.70) measured 2 weeks after admission. Sensitivity was similar, but specificity was significantly better in patients with alcohol compared to (illicit) drugs as the primary substance of abuse (0.76 vs. 0.56). ASRS was not a good screener for externalizing disorders other than ADHD. CONCLUSIONS: The ASRS is a sensitive screener for identifying possible ADHD cases with very few missed cases among those screening negative in this population.
BACKGROUND: To detect attention deficit hyperactivity disorder (ADHD) in treatment seeking substance use disorders (SUD) patients, a valid screening instrument is needed. OBJECTIVES: To test the performance of the Adult ADHD Self-Report Scale V 1.1(ASRS) for adult ADHD in an international sample of treatment seeking SUD patients for DSM-IV-TR; for the proposed DSM-5 criteria; in different subpopulations, at intake and 1-2 weeks after intake; using different scoring algorithms; and different externalizing disorders as external criterion (including adult ADHD, bipolar disorder, antisocial and borderline personality disorder). METHODS: In 1138 treatment seeking SUD subjects, ASRS performance was determined using diagnoses based on Conner's Adult ADHD Diagnostic Interview for DSM-IV (CAADID) as gold standard. RESULTS: The prevalence of adult ADHD was 13.0% (95% CI: 11.0-15.0%). The overall positive predictive value (PPV) of the ASRS was 0.26 (95% CI: 0.22-0.30), the negative predictive value (NPV) was 0.97 (95% CI: 0.96-0.98). The sensitivity (0.84, 95% CI: 0.76-0.88) and specificity (0.66, 95% CI: 0.63-0.69) measured at admission were similar to the sensitivity (0.88, 95% CI: 0.83-0.93) and specificity (0.67, 95% CI: 0.64-0.70) measured 2 weeks after admission. Sensitivity was similar, but specificity was significantly better in patients with alcohol compared to (illicit) drugs as the primary substance of abuse (0.76 vs. 0.56). ASRS was not a good screener for externalizing disorders other than ADHD. CONCLUSIONS: The ASRS is a sensitive screener for identifying possible ADHD cases with very few missed cases among those screening negative in this population.
Authors: J B Williams; M Gibbon; M B First; R L Spitzer; M Davies; J Borus; M J Howes; J Kane; H G Pope; B Rounsaville Journal: Arch Gen Psychiatry Date: 1992-08
Authors: Ronald C Kessler; Lenard A Adler; Michael J Gruber; Chaitanya A Sarawate; Thomas Spencer; David L Van Brunt Journal: Int J Methods Psychiatr Res Date: 2007 Impact factor: 4.035
Authors: M Arcos-Burgos; M Jain; M T Acosta; S Shively; H Stanescu; D Wallis; S Domené; J I Vélez; J D Karkera; J Balog; K Berg; R Kleta; W A Gahl; E Roessler; R Long; J Lie; D Pineda; A C Londoño; J D Palacio; A Arbelaez; F Lopera; J Elia; H Hakonarson; S Johansson; P M Knappskog; J Haavik; M Ribases; B Cormand; M Bayes; M Casas; J A Ramos-Quiroga; A Hervas; B S Maher; S V Faraone; C Seitz; C M Freitag; H Palmason; J Meyer; M Romanos; S Walitza; U Hemminger; A Warnke; J Romanos; T Renner; C Jacob; K-P Lesch; J Swanson; A Vortmeyer; J E Bailey-Wilson; F X Castellanos; M Muenke Journal: Mol Psychiatry Date: 2010-02-16 Impact factor: 15.992
Authors: Geurt Van de Glind; Christoffer Brynte; Arvid Skutle; Sharlene Kaye; Maija Konstenius; Frances Levin; Frieda Mathys; Zsolt Demetrovics; Franz Moggi; Josep Antoni Ramos-Quiroga; Arnt Schellekens; Cleo Crunelle; Geert Dom; Wim van den Brink; Johan Franck Journal: Eur Addict Res Date: 2020-06-29 Impact factor: 3.015
Authors: Cleo L Crunelle; Wim van den Brink; Franz Moggi; Maija Konstenius; Johan Franck; Frances R Levin; Geurt van de Glind; Zsolt Demetrovics; Corné Coetzee; Mathias Luderer; Arnt Schellekens; Frieda Matthys Journal: Eur Addict Res Date: 2018-03-06 Impact factor: 3.015
Authors: Franz Moggi; Deborah Schorno; Leila Maria Soravia; Meichun Mohler-Kuo; Natialia Estévez-Lamorte; Joseph Studer; Gerhard Gmel Journal: Eur Addict Res Date: 2020-06-19 Impact factor: 3.015
Authors: Daniel P Notzon; Martina Pavlicova; Andrew Glass; John J Mariani; Amy L Mahony; Daniel J Brooks; Frances R Levin Journal: J Atten Disord Date: 2016-03-31 Impact factor: 3.256